Despite evidence suggesting there is an impact of physical activity and body mass index on the risk for Parkinson disease, a large prospective study published in Neurology shows that there is no significant association between prolonged sitting/inactivity or obesity with PD risk.
Patients with TBI had a higher incidence of PD compared with patients without TBI.
The assessment of psychiatric symptoms relied on only one question in the MDS-UPDRS, potentially leading to underestimation of these symptoms in this cohort.
Several prodromal symptoms in REM sleep behavior disorder are highly associated with conversion to neurodegenerative diseases.
Wearable technology may help monitor on/off states in patients with Parkinson disease in an outpatient setting.
ADS-5102 is a promising treatment option: if taken once daily at night, it achieves highest plasma drug concentrations throughout the day when symptoms are most bothersome.
Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.
Parkinsonism syndromes are associated with progressive disability and increased mortality, with symptom burden comparable to that of advanced cancer.
Post-LFP change aDBS was deemed safe, tolerable, and effective among patients performing regular daily activities who were also taking additional dopaminergic drugs.
Significant between-group differences in acetylcholinesterase hydrolysis rates were observed among patients with LRRK2 PD, idiopathic PD, LRRK2 mutation carriers without PD, and healthy controls.
The SPAN-PD trial found that Inbrija 84mg improved motor functions in Parkinson Disease experiencing off periods.
Utilizing 123I-FP-CIT SPECT imaging of raphe serotonergic nuclei and putamen dopaminergic terminals may help detect factors that influence response to dopaminergic treatment.
Anesthetic medications have been identified as a potential cause of morbidity in this population due to their interaction with the drugs used to manage Parkinson disease.
The ParkinsonNet network was associated with reduced overall health care costs.
The neuroprotective effect of caffeine has previously been examined in epidemiologic studies.
The incidence of impulsive compulsive behaviors in patients with Parkinson's may be related to excessive stimulation of dopamine.
The findings suggest that efforts to help prevent anxiety may help reduce risk for gait freezing.
High-intensity treadmill exercise appears to be a safe and tolerable option for physical activity in patients with Parkinson disease.
The diagnosis of Parkinson disease is made mostly through a clinical assessment of motor signs and symptoms, which appear when approximately 70% of nigral neurons are lost.
Patients with dyskinesia had a significantly higher frequency of impulse control disorders.
MRI may be used to identify Parkinson disease biomarkers that can inform diagnosis, track disease progression, and elucidate the neurobiological underpinnings of symptoms.
Given the prevalence of depression in Parkinson's disease and the effectiveness of antidepressants, health care providers should promote adherence in clinical practice.
There is a higher risk of death from Parkinson's disease or ALS in white collar workers.
Dopamine deficiency, decreases in cortical thickness and volume in certain areas of the brain was predictive of cognitive decline.
Patients in the treatment group had improved ON and OFF times and no worsening of motor function.
Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.
However, there is a trend toward lower risk of Parkinson's for patients with truncal vagotomy.
Dextromethorphan is thought to have an impact on all 3 therapeutic pathways for dyskinesia.
Jori Fleisher, MD, MSCE, of New York University School of Medicine, discusses her research on an interdisciplinary home visit program for patients with advanced Parkinson's disease. Scroll below the video for the full transcript.
A patient should be notified of the possibility of developing an ICD before initiating any dopaminergic treatment for PD, particularly dopamine agonists.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics